# AstraZeneca: Phase 3 study closed enrollment, 1051 enrolled (Non-Small Cell Lung Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer |
| NCT ID | NCT05221840 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention types | drug, other |
| Target enrollment | 1051 |
| Site countries | United States, Australia, Brazil, Canada, China, Colombia, France, Germany, Italy, Japan, Peru, Poland |
| Posted | 2022-02-03 |
| Planned start | 2022-02-07 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-04 |
| Last update posted | 2026-11-04 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1051 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05221840). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.